
Following on from our successful
National Institute for Health Research (NIHR) Diagnostic Evidence Co-operative Newcastle (DEC), which ran from 2013-2017, and a
fter a competitive national process, Newcastle has been chosen to host one of the NIHR MedTech and In Vitro Diagnostics Co-operatives (MIC) effective from January 2018.
Our new website is currently under development. We will continue to update this one until it's ready! Please check back again soon!
The NIHR Newcastle In Vitro Diagnostics Co-operative (Newcastle MIC) is one of 11 MICs set up to provide a centre for excellence for the development and evaluation of new effective diagnostic tests. We will work closely with the diagnostics industry and build expertise and capacity in the NHS to provide evidence on new In Vitro Diagnostics (IVD), medical
tests which use a sample of tissue or bodily fluid. This will enable the test to
be introduced more rapidly and effectively for patient benefit. Other MICs help to develop new medical technologies.

The Newcastle MIC is a partnership between Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. We will build collaborations with: the diagnostic industry; clinicians and other healthcare professionals; patient groups; commissioners; academic researchers including heath economists and other NIHR MICs.
The Newcastle MIC facilitates the generation of high quality evidence on clinical validity, utility and cost-effectiveness of In Vitro diagnostic medical tests (IVDs) for use in the NHS.
For more information see About us
Newly funded NIHR Medtech and In Vitro Diagnostic Co-operatives announced
To coincide with the publication of the Life Science Industrial Strategy, Health Secretary Jeremy Hunt, announces £14.25 million funding to support 11 NIHR Medtech and In Vitro Diagnostic Co-operatives (MICs).
News & Development
News!NIHR DEC Newcastle play key role in development of NICE GuidelineFamilial hypercholesterolaemia: identification and managementEvidence reviews for case-finding, diagnosis and statin monotherapy |